Impact of a novel oral medication delivery device on patient engagement and discontinuation in individuals receiving oral oncolytic medications.
Taylor M, Fuhr K, Heiland K, Huntington S, Lustberg M, Schellhorn S. Impact of a novel oral medication delivery device on patient engagement and discontinuation in individuals receiving oral oncolytic medications. Journal Of Clinical Oncology 2025, 43: 11063-11063. DOI: 10.1200/jco.2025.43.16_suppl.11063.Peer-Reviewed Original ResearchPatient-reported outcomesHistorical control groupDose reductionControl groupAdverse event-related discontinuationsEvaluate dose reductionMedication delivery devicesHistorical control cohortTime of dosingDelivery devicesRibociclib groupEarly toxicityDiscontinuation ratesMedian ageMedication toleranceAcute care utilizationClinical outcomesHistorical controlsOral medicationsRibociclibControl cohortTreatment adjustmentMedication discontinuationAcalabrutinibCohort of individuals
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply